These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript.pdf (2.42 MB)

Gibberellin JRA-003: A Selective Inhibitor of Nuclear Translocation of IKKalpha

submitted on 16.12.2019 and posted on 20.12.2019 by James Annand, Andrew Henderson, Kyle Cole, Aaron Maurais, Jorge Becerra, Yejun Liu, Eranthie Weerapana, Angela Koehler, Anna Mapp, Corinna Schindler
The small molecule gibberellin JRA-003 (1) was identified as an inhibitor of the NF-kB (nuclear kappa-light-chain enhancer of activated B cells) pathway. Here we find that JRA-003 binds to and significantly inhibits the nuclear translocation of pathway-activating kinases IKKalpha (IkB kinase alpha) and IKKbeta (IkB kinase beta). Analogs were synthesized and NF-kB-inhibiting gibberellins were found to be cytotoxic in cancer-derived cell lines (HS 578T, HCC 1599, RC-K8, Sud-HL4, CA 46, and NCIH 4466). Not only was JRA-003 (1) identified as the most potent synthetic gibberellin against cancer-derived cell lines, it displayed no cytotoxicity in cells derived from non-cancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC). This selectivity suggests a promising approach for the development of new therapeutics.


David and Lucile Packard Foundation

Alfred P. Sloan Foundation

Camille and Henry Dreyfus Foundation

Koch Institute Cancer Center Support Core Grant (P30-CA14051)


Email Address of Submitting Author


University of Michigan


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest


Logo branding